A comparative study of efficacy and safety of the lyophilized powder alpha-erythropoietin and the liquid form alpha-erythropoietin for hemoglobin maintenance in XXXX with hemodialysis treatment.

@entity1 @entity8 @entity417 @entity69 @entity1307 @entity740
BACKGROUND: Insufficient production oferythropoietin ( @entity1307 ) is the primary cause ofanemia in @entity1 with @entity740 ( @entity740 ). The @entity1307 treatment is an established treatment for @entity8 . The study investigated the therapeutic outcome between lyophilized powder and liquid form of @entity1307 alpha by intravenous (IV) administration in hemoglobin maintenance of anemic treatment for @entity740 @entity1 receiving hemodialysis. MATERIAL AND METHOD: Forty @entity1 were randomly assigned to either lyophilized powder of @entity1307 alpha (treatment, n = 21) or liquidform of @entity1307 alpha (control, n = 19) for 12 weeks by lVadministration. The hemoglobin was maintained within the target range of 10. 0 to 12.0 g/dL by adjusting the dosage of @entity1307 . The clinical and biochemical profiles including @entity69 saturation andferritin were measured. Adverse events were documented. RESULTS: The mean hemoglobin ofboth groups at baseline was 11.2  0.6 g/dL. Mean hemoglobin and mean hematocrit levels at baseline, and follow-up data of both groups were not statistically different. The mean weekly dosage of @entity1307 in the treatment and control groups had no statistical significance within the same group and between groups as well. Stable hemoglobin levels were maintained without @entity1307 dosage adjustment in the majority ofpatients in both groups (treatment group, 90.5%, control group, 94.7%). During the 12-week study period, no serious side effect was detected CONCLUSION: The present study demonstrated that the lyophilizedpowder ofEPO alpha was effective and safe as the standard liquid form of @entity1307 alpha when it was administered by IV route in hemoglobin maintenance of @entity417 treatment.
